It has been shown that targeting gefitinib and everolimus can inhibit the activation of the PI3K/AKT/mTOR signaling pathway, thereby blocking cancer cell cycle progression and promoting apoptosis in TNBC cells [108]. This evidence concerns the gene MTOR and cancer.